BDSX - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Biodesix, Inc.

Management's high level of expertise in test commercialization ensures transparency of financial flows. The last twelve months (LTM) growth rate of commercial revenue confirms this trajectory, where 30.80 captures the magnitude of this parameter. Biodesix, Inc. (BDSX) leadership in lung liquid biopsy is based on the rapid analysis of proteins and genes, while the company actively recruits AI and bioinformatics specialists to develop its diagnostic systems.
פילוחי נתונים אנליטיים מרוכזים עבור Biodesix Corporation (BDSX)

This indicator assesses revenue dynamics over a rolling year, allowing for a comparison of the asset's market value with its actual resilience. By analyzing the 12-month year-over-year revenue growth rate, an investor can see the percentage change in sales relative to the same period last year. This metric measures the speed of business scaling and the effectiveness of the commercial strategy. For Biodesix, Inc. (BDSX), this trend reflects the successful implementation of Nodify AI diagnostics. The growth confirms market adoption of non-invasive tests that replace traditional biopsies.